---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Mechanism of action"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Mechanism of action. Topics: Prekallikrein mRNA degradation in the liver, RNA interference: RISC-mediated cleavage of target mRNA, Congress reports: prekallikrein mRNA cleavage and bradykinin generation, Molecular structure and hepatic targeting, and 2 further topics. 6 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Prekallikrein mRNA degradation in the liver

> “Onvuzosiran’s mechanism of action is designed to degrade PKK mRNA in the liver, thereby resulting in the reduction of plasma kallikrein levels by preventing the production of its proenzyme, PKK.”
> “Onvuzosiran is designed to reduce bradykinin by selectively silencing PKK mRNA for degradation in the liver and prevent protein synthesis.”
> “This reduces circulating PKK protein levels and prevents activation of the bradykinin pathway that underlies HAE attacks”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.1-2"></a>

### RNA interference: RISC-mediated cleavage of target mRNA

> “A protein complex known as RISC recognizes the siRNA duplex, and an endogenous nuclease, Argonaute 2 (Ago2), unravels the duplex, discards the passenger strand and retains the guide strand, forming the loaded RISC.”
> “Once the siRNA guide strand is hybridized to the target mRNA, the RISC cleaves the mRNA, leading to its degradation and preventing the translation of the mRNA into protein.”
> “Unlike ASOs, which employ a different mechanism as a single strand construct, siRNAs remain bound to the RISC, silencing multiple mRNA copies, resulting in long-term PD effects.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.1-3"></a>

### Congress reports: prekallikrein mRNA cleavage and bradykinin generation

> “ADX-324 is an investigational siRNA therapy designed to inhibit prekallikrein (PKK) generation at the mRNA level and reduce the production of plasma PKK, thereby averting bradykinin generation and potentially preventing HAE attacks.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “ADX-324 is an investigational siRNA that cleaves prekallikrein (PKK) mRNA, thereby preventing HAE attacks.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “ADX-324 is an investigational siRNA that strongly inhibits the production of prekallikrein (PKK), reducing bradykinin generation, preventing HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “ADX-324 is a siRNA duplex oligonucleotide that inhibits prekallikrein (PKK), offering the possibility of prevention of HAE attacks by a single subcutaneous injection every six months.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-2.1.2.6.1-4"></a>

### Molecular structure and hepatic targeting

> “prekallikrein synthesis reducer”

Source: [World Health Organization (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

> “GalNAc3-conjugated siRNA targeting hepatic prekallikrein mRNA”
> “It selectively targets hepatic prekallikrein mRNA to reduce prekallikrein production.”

Source: [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)

<a id="topic-2.1.2.6.1-5"></a>

### Distinction from gene therapy

> “It’s important to note that ADX-324 is not a gene-therapy and does not change a person’s DNA.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-2.1.2.6.1-6"></a>

### Hepatic targeting for novel prophylactic therapies: review

> “This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials.”

Source: [Riedl et al. (2024a)](https://pure.amsterdamumc.nl/en/publications/clinical-progress-in-hepatic-targeting-for-novel-prophylactic-the)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
